Caliway Showcases CBL-514 Obesity Combination Data at ECO 2026
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
metabolic health
Advertisement
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
Phase II Data Support MCS-8 Potential in Cancer Prevention
NEW TAIPEI CITY, Taiwan, Jan. 30, 2026 — Jyong Biotech announced updated Phase II clinical trial results for its...
Jupiter Expands Nugevia™ Strategy for GLP-1 Users
Jupiter, Florida | January 28, 2026 — Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, announced a strategic expansion of...
Advertisement
